Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$2.77 USD
-0.07 (-2.46%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.77 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GALT 2.77 -0.07(-2.46%)
Will GALT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GALT
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
GALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
Other News for GALT
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024
Galectin Therapeutics GAAP EPS of -$0.20
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Galectin Therapeutics reports Q2 EPS (20c) vs. (15c) last year